Background/Aims: To determine adult statures and linear growth patterns of children with growth hormone deficiency (GHD) who began treatment with recombinant human growth hormone (rhGH) in infancy. Methods: Forty-seven patients with GHD in whom administration of rhGH was initiated at or before 2 years of age and who had achieved near-adult heights (NAH) were identified in the database of the Genentech National Cooperative Growth Study. Results: After beginning treatment at a mean age of 0.9 years and height of –2.3 SD, these subjects achieved mean statures of –0.6, –0.3, and –0.4 SD at 5 and 10 years of age and at NAH, respectively. In 23 patients whose parental heights were known, mean NAH was comparable to the target height. Patients with uncomplicated courses whose heights were normal or tall when spontaneous puberty occurred or was induced realized the tallest NAHs. Patients with severe prenatal or perinatal, congenital and acquired neurologic insults, sexual precocity, or associated illnesses achieved less optimal NAHs. Conclusion: A normal pattern of linear growth during childhood and adolescence and satisfactory NAHs can be achieved in the majority of patients when treatment of the GHD subject is begun during infancy.

Raben MS: Treatment of a pituitary dwarf with human growth hormone. J Clin Endocrinol Metab 1958;18:901–903.
Raben MS: Growth hormone. 2. Clinical use of human growth hormone. N Engl J Med 1962;266:82–86.
Guyda HJ: Four decades of growth hormone therapy for short children: what have we accomplished? J Clin Endocrinol Metab 1999;84:4307–4316.
Blethen SL, Baptista J, Kuntze J, et al: Adult height in growth hormone (GH)-deficient children treated with biosynthetic GH. J Clin Endocrinol Metab 1997;82:418–420.
Thomas M, Massa G, Bourguignon J-P, et al: Final height in children with idiopathic growth hormone deficiency treated with recombinant human growth hormone: the Belgian experience. Horm Res 2000;55:88–94.
Harris M, Hoffman PL, Cutfield WS: Growth hormone treatment in children. Review of safety and efficacy. Pediatr Drugs 2004;6:93–106.
Maghnie M, Ambrosini L, Cappa M, et al: Adult height in patients with permanent growth hormone deficiency with and without multiple pituitary hormone deficiencies. J Clin Endocrinol Metab 2006;91:2900–2905.
Reiter EO, Price DA, Wilton P, et al: Effect of growth hormone (GH) on the near-final height of 1258 patients with idiopathic GH deficiency: analysis of a large international database. J Clin Endocrinol Metab 2006;91:2047–2054.
August GP, Lippe BM, Blethen SJ, et al: Growth hormone treatment in the United States: demographic and diagnostic features of 2331 children. J Pediatr 1990;116:899–903.
Malozowski S, Stadel BV: Prepubertal gynecomastia during growth hormone therapy. J Pediatr 1995;126:659–661.
Ranke MB, Lindberg A, Martin DD, et al: The mathematical model for total pubertal growth in idiopathic growth hormone (GH) deficiency suggests a moderate role of GH dose. J Clin Endocrinol Metab 2003;88:4748–4753.
Ranke MB, Lindberg A, Albertsson-Wikland K, et al: Increased response, but lower responsiveness, to growth hormone (GH) in very young children (aged 0–3 years) with idiopathic GH deficiency: analysis of data from KIGS. J Clin Endocrinol Metab 2005;90:1966–1971.
Boersma B, Rikken B, Wit JM, et al: Catch-up growth in early treated patients with growth hormone deficiency. Arch Dis Child 1995;72:427–431.
Arrigo T, De Luca F, Bernasconi S, et al: Catch-up growth and height prognosis in early treated children with congenital hypopituitarism. Horm Res 1995;44(suppl 3):26–31.
Rappaport R, Mugnier E, Limoni C, et al: A 5-year prospective study of growth hormone (GH)-deficient children treated with GH before the age of 3 years. J Clin Endocrinol Metab 1997;82:452–456.
De Luca F, Arrigo T, Bozzola M, et al: L’hypopituitarisme au cours de la première année de vie: étude italienne collaborative. Arch Pediatr 1998;5(suppl 4):313–317.
Huet F, Carel J-C, Nivelon J-L, Chaussain J-L: Long-term results of GH therapy in GH-deficient children treated before 1 year of age. Eur J Endocrinol 1999;140:29–34.
Ben-Signor C, Carel J-C, Polack M, et al: Final height of growth hormone deficient patients treated before one year of age: a therapeutic model. Horm Res 2009;72(suppl 3): 45–46.
Attanasio AF, Howell S, Bates PC, et al: Confirmation of severe GH deficiency after final height in patients diagnosed as GH deficient during childhood. Clin Endocrinol 2002;56:503–507.
Tauber M, Moulin P, Pienkowski C, et al: Growth hormone (GH) retesting and auxological data in 131 GH-deficient patients after completion of treatment. J Clin Endocrinol Metab 1997;82:352–356.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.